Novai

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Novai is a British biotechnology company, developing and commercialising transformational and disruptive technology in the ophthalmology area developed by Professor M Francesca Cordeiro at UCL and Imperial College, through Wellcome Trust Innovation funding.
Professor Cordeiro developed DARC (Detection of Apoptosing Retinal Cells) over the last decade with a vision of improving patients’ lives through early diagnosis of neurodegenerative diseases with the ultimate aim of preventing functional loss.
DARC consists of a biological marker combined with an Artificial Intelligence (AI) aided algorithm.
Together the technology identifies cellular level disease activity in the retina. In a recently published Phase II study (May 3rd, 2020), exciting data showed that using an AI-aided algorithm, DARC was able to predict progressive glaucomatous damage 18 months ahead of that seen with the current gold standard, OCT retinal imaging technology. New data on DARC in predicting AMD expected Q3.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
2020
Main Therapeutic Focus:
Lead Product in Development:
Glaucoma biomarker
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Acting CEO
Novai